Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag in Platelet Refractory Thrombocytopenia
NCT01194167Phase 2
Key facts
- Status
- Withdrawn
- Start
- Aug 2010
- Primary completion
- Jan 2012
- Countries
- 1
- Sponsor
- University of Cincinnati
- Modality
- Small Molecules
- Drugs
- eltrombopag
- Conditions
- Thrombocytopenia
01
Overview
Phase 2, open-label trial of eltrombopag in Thrombocytopenia, sponsored by University of Cincinnati. Primary endpoint: Platelet transfusion independence at 3 years. Planned start Aug 2010; status: withdrawn.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Patients with platelet refractory and dependent thrombocytopenia with adequate organ function.
04
Endpoints
Primary
Platelet transfusion independence
Beyond the preview
Go deeper on NCT01194167.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01194167.